China Life Private Equity Investment

Overview

Established in June 2016, China Life Private Equity Investment Co., Ltd. is a professional alternative investment platform under China Life Insurance Company. The firm leverages China Life's extensive resources to serve as a long-term value investor and partner. It is committed to providing trustworthy investment management services and integrated investment and financing solutions to the industry. The firm's investment strategy encompasses a diverse range of sectors, including healthcare, biotechnology, pharmaceutical, life science, medical device, information technology, 3D technology, manufacturing, and more. It actively invests in early-stage, growth, late-stage, pre-IPO, and buyout opportunities, primarily focusing on the Chinese market. China Life Private Equity has received numerous accolades for its contributions to the private equity industry. Notably, in 2016, it was recognized as one of the '10 Most Competitive Private Equity Investors of the Year' by Zero2IPO Group. In 2019, it received the 'Golden Bull Award of New Prominent Equity Investor' from the Chinese Securities Journal. These honors reflect the firm's commitment to excellence and its significant impact on the investment landscape. Investment Requirements: The firm typically invests in rounds with four participants, with deal sizes ranging from $10 million to $50 million. Startups seeking investment are generally expected to be 2-3 years old. The firm has a history of leading investments in various sectors, including healthcare and biotechnology. Year Founded: 2016

Investment Focus

• Investments in rounds with four participants
• Deal sizes ranging from $10 million to $50 million
• Startups generally 2-3 years old

Portfolio Companies